TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01991561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of H5 VLP vaccine + Alhydrogel
Description: Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Med dose of H5 VLP vaccine + Alhydrogel
Description: Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of H5 VLP vaccine + Alhydrogel
Description: Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of H5 VLP vaccine + GLA-SE
Description: Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of H5 VLP vaccine + GLA-SE
Description: Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: Placebo
Description: Biological: Placebo 2 doses given 21 days apart of the placebo
Study: NCT01300104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.~Restrictions: None.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole grain rye
Description: Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommendations
Description: Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recommendations
Description: Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
Study: NCT01875497

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: grape fruit (vitis vinifera) extract in capsule with 205 mg
Description: Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
Study: NCT02532231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02935972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: received intravenous diazepam 5 mg slowly just before TRUS probe insertion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1%
Description: received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam and Lidocaine 1%
Description: received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
Study: NCT04194060

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery after Surgery group
Description: * Tracheal intubation and with General anesthesia~* Short acting anesthetic agents,avoid opioid agents~* Omental patch repair with placement of sub hepatic drain~* Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~* Post operative nausea and vomiting prophylaxis.~* Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~* Initiation of feeding-Oral sips on day 1, step up day 2 onward~* Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~* Removal of urinary catheter-after weaning from the effect of general anesthesia.~* Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~* Avoid opiod analgesics.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Tracheal intubation~* Short acting anesthetic agents, avoid opiod anesthesia agents.~* Omental patch repair along with sub hepatic drain placement.~* Post operative nausea and vomiting prophylaxis.~* Ambulation-as per patients' own request.~* Initiation of oral feed- after passage of 1st flatus.~* Nasogastric tube removal-output \<300ml/day with resolution of ileus.~* Removal of urinary catheter- when patient sits on bed side/ambulate.~* Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~* Patient will receive opiod analgesics.
Study: NCT02144272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3114062 SC
Description: LY3114062 administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3114062 IV
Description: LY3114062 administered IV.
Study: NCT03009604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: Simethicone 40mg oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enema
Description: sodium dihydrogen phosphate dihydrate 19.2 gram \& disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
Study: NCT02420834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose
Description: Tear supplement to be taken as required to relieve symptoms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liposomal Spray
Description: Tear supplement o be taken as required to relieve symptoms
Study: NCT03004105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: About every 6 months, participant called by a member of the study staff to ask how participant is doing and if participant has started any new treatments outside of the study. These calls should last about 10 minutes each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: About every 6 months, participant called by a member of the study staff to ask how participant is doing and if participant has started any new treatments outside of the study. These calls should last about 10 minutes each time.
Study: NCT01110473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348 and azacitidine
Description: An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Study: NCT03351335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound with visualization
Description: All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound with visualization
Description: All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound with visualization
Description: All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.
Study: NCT01185847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: intravenously, until disease progression
Study: NCT00890526

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Counseling
Description: Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
Study: NCT01185847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: intravenously, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: standard treatment, up to 6 cycles
Study: NCT00890526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Sound Therapy
Description: The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sound Therapy
Description: The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
Study: NCT02489526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
Study: NCT01185847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: standard treatment, up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: standard treatment, up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: standard treatment, up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: standard treatment, up to 6 cycles
Study: NCT02489526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive the corresponding amount of placebo.
Study: NCT01458561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFoam Surgical Matrix
Description: Surgical adjunct to control bleeding in open liver surgery
Study: NCT01185847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: standard treatment, up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: standard treatment, up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: standard treatment, up to 6 cycles
Study: NCT02379325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lets Quit
Description: Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lets Quit
Description: Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pamphlets material
Description: Given pamphlets material on smoking and complication

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pamphlets material
Description: Given pamphlets material on smoking and complication
Study: NCT01220414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone, then placebo
Description: 50 mg of naltrexone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone, then placebo
Description: 50 mg of naltrexone
Study: NCT01458561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam Plus
Description: Surgical adjunct in control of bleeding in open liver surgery
Study: NCT01777347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Saline
Description: Two 4 mL nebulization of 3% saline with 20 minutes interval
Study: NCT01220414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, then Naltrexone
Description: sugar pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, then Naltrexone
Description: sugar pill
Study: NCT01150487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspirations
Description: A bone marrow aspiration from each hip bone of the patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node collection
Description: An Iliac lymph node collection.
Study: NCT02310048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-FormA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-FormB
Study: NCT02507479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Chemotherapy given prior to allogeneic stem cell transplantation
Study: NCT01734876

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tactile Touch
Description: Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile Touch
Description: Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rest To Music
Description: Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rest To Music
Description: Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
Study: NCT04764435

Intervention type: OTHER
Intervention: Physician ownership
Description: The intervention or exposure is whether the dialysis facility was owned by a physician in 2017
Study: NCT01777347

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
Study: NCT04764435

Intervention type: OTHER
Intervention: Large dialysis organization ownership
Description: The intervention or exposure is whether the dialysis facility was owned by a large dialysis organization in 2017
Study: NCT01424592

Intervention type: DEVICE
Intervention: Testing with a portable sleep apnea monitor .
Description: Portable sleep apnea testing will performed on referred patients.
Study: NCT01536574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Requip PR
Description: Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
Study: NCT01216839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
Study: NCT02108119

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo
Study: NCT03210480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium sulphate prolonged-release 660 mg
Description: Oral administration of one tablet once or twice daily (one tablet in the morning and one tablet in the evening) or two tablets in a single dose (two tablets in the evening) of Lithium sulphate 660 mg (Lithium sulphate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium carbonate immediate-release 150 mg and 300 mg
Description: Oral administration of 300-1800 mg daily divided into 2-6 doses of Lithium carbonate capsules (Lithium carbonate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
Study: NCT03569761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorectal Cancer Screening Decision Aid
Description: Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments. Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
Study: NCT03060694

Intervention type: OTHER
Intervention: diabetes
Description: 1. a history of diabetes and using anti-diabetic medicines.~2. fasting serum glucose level greater than 7.1mmol/L, or glycosylated hemoglobin percentage greater than 6.5%.
Study: NCT03808064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCHV home visit
Description: Behavioral: FCHV visit Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages Other Name: FCHV Home Visit
Study: NCT03173391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: BID Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID Oral administration
Study: NCT02973763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alflutinib
Study: NCT01805180

Intervention type: DEVICE
Group type: OTHER
Intervention: Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)
Description: In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.

Intervention type: DEVICE
Group type: OTHER
Intervention: Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)
Description: In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.

Intervention type: DEVICE
Group type: OTHER
Intervention: Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)
Description: In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.

Intervention type: DEVICE
Group type: OTHER
Intervention: Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)
Description: In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.